Standard

The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts. / Westerhof, Ilse; de Hoog, Marieke; Ieven, Margareta et al.

In: International Journal of Infectious Diseases, Vol. 128, 01.03.2023, p. 140-147.

Research output: Contribution to journal › Article › Academic › peer-review

Harvard

Westerhof, I, de Hoog, M, Ieven, M, Lammens, C, van Beek, J, Rozhnova, G, Eggink, D, Euser, S, Wildenbeest, J, Duijts, L, van Houten, M, Goossens, H, Giaquinto, C & Bruijning?Verhagen, P 2023, 'The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts', International Journal of Infectious Diseases, vol. 128, pp. 140-147. https://doi.org/10.1016/j.ijid.2022.12.018

APA

Westerhof, I., de Hoog, M., Ieven, M., Lammens, C., van Beek, J., Rozhnova, G., Eggink, D., Euser, S., Wildenbeest, J., Duijts, L., van Houten, M., Goossens, H., Giaquinto, C., & Bruijning?Verhagen, P. (2023). The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts. International Journal of Infectious Diseases, 128, 140-147. https://doi.org/10.1016/j.ijid.2022.12.018

Vancouver

Westerhof I, de Hoog M, Ieven M, Lammens C, van Beek J, Rozhnova G et al. The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts. International Journal of Infectious Diseases. 2023 Mar 1;128:140-147. doi: 10.1016/j.ijid.2022.12.018

Author

Westerhof, Ilse ; de Hoog, Marieke ; Ieven, Margareta et al. / The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts. In: International Journal of Infectious Diseases. 2023 ; Vol. 128. pp. 140-147.

BibTeX

@article{2fed8bc3787a472abe96e19dae29ddc4,
title = "The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts",
abstract = "Objectives: We compared age-stratified SARS-CoV-2 symptomatology of wild-type/Alpha vs Omicron BA.1/BA.2 variant infected individuals and the impact of COVID-19 booster vaccination on Omicron symptom burden. Methods: Data from three European prospective household cohorts were used (April 2020 to April 2021 and January to March 2022). Standardized outbreak protocols included (repeated) polymerase chain reaction testing, paired serology, and daily symptom scoring for all household members. Comparative analyses were performed on 346 secondary household cases from both periods. Results: Children <12 years (all unvaccinated) experienced more symptoms and higher severity scores during Omicron compared with wild-type/Alpha period (P ≤0.01). In adults, Omicron disease duration and severity were reduced (P ≤ 0.095). Omicron was associated with lower odds for loss of smell or taste (adjusted odds ratio [aOR]: 0.14; 95% CI 0.03-0.50) and higher but non-significant odds for upper respiratory symptoms, fever, and fatigue (aORs: 1.85-2.23). No differences were observed in disease severity or duration between primary vs booster series vaccinated adults (P ≥0.12). Conclusion: The Omicron variant causes higher symptom burden in children compared with wild-type/Alpha and lower in adults, possibly due to previous vaccination. A shift in symptoms occurred with reduction in loss of smell/taste for Omicron. No additional effect of booster vaccination on Omicron symptom burden was observed.",
keywords = "COVID-19 vaccination, Epidemiology, European prospective household studies, Omicron BA.1 and BA.2 variant, SARS-CoV-2 symptom burden, Wild-type/Alpha variant",
author = "Ilse Westerhof and {de Hoog}, Marieke and Margareta Ieven and Christine Lammens and {van Beek}, Janko and Ganna Rozhnova and Dirk Eggink and Sjoerd Euser and Joanne Wildenbeest and Liesbeth Duijts and {van Houten}, Marlies and Herman Goossens and Carlo Giaquinto and Patricia Bruijning?Verhagen",
note = "Funding Information: This work forms part of RECOVER (Rapid European COVID-19 Emergency Response research) and VERDI (SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts). RECOVER (101003589) is funded by the European Union (EU) Horizon 2020 research and innovation program. VERDI project (101045989) is funded by the EU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the EU or the European Health and Digital Executive Agency. Neither the EU nor the granting authority can be held responsible for them. In addition, part of the work is funded by ZonMw. Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2023",
month = mar,
day = "1",
doi = "10.1016/j.ijid.2022.12.018",
language = "English",
volume = "128",
pages = "140--147",
journal = "International journal of infectious diseases : IJID",
issn = "1201-9712",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts

AU - Westerhof, Ilse

AU - de Hoog, Marieke

AU - Ieven, Margareta

AU - Lammens, Christine

AU - van Beek, Janko

AU - Rozhnova, Ganna

AU - Eggink, Dirk

AU - Euser, Sjoerd

AU - Wildenbeest, Joanne

AU - Duijts, Liesbeth

AU - van Houten, Marlies

AU - Goossens, Herman

AU - Giaquinto, Carlo

AU - Bruijning?Verhagen, Patricia

N1 - Funding Information: This work forms part of RECOVER (Rapid European COVID-19 Emergency Response research) and VERDI (SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts). RECOVER (101003589) is funded by the European Union (EU) Horizon 2020 research and innovation program. VERDI project (101045989) is funded by the EU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the EU or the European Health and Digital Executive Agency. Neither the EU nor the granting authority can be held responsible for them. In addition, part of the work is funded by ZonMw. Publisher Copyright: © 2022 The Author(s)

PY - 2023/3/1

Y1 - 2023/3/1

N2 - Objectives: We compared age-stratified SARS-CoV-2 symptomatology of wild-type/Alpha vs Omicron BA.1/BA.2 variant infected individuals and the impact of COVID-19 booster vaccination on Omicron symptom burden. Methods: Data from three European prospective household cohorts were used (April 2020 to April 2021 and January to March 2022). Standardized outbreak protocols included (repeated) polymerase chain reaction testing, paired serology, and daily symptom scoring for all household members. Comparative analyses were performed on 346 secondary household cases from both periods. Results: Children <12 years (all unvaccinated) experienced more symptoms and higher severity scores during Omicron compared with wild-type/Alpha period (P ≤0.01). In adults, Omicron disease duration and severity were reduced (P ≤ 0.095). Omicron was associated with lower odds for loss of smell or taste (adjusted odds ratio [aOR]: 0.14; 95% CI 0.03-0.50) and higher but non-significant odds for upper respiratory symptoms, fever, and fatigue (aORs: 1.85-2.23). No differences were observed in disease severity or duration between primary vs booster series vaccinated adults (P ≥0.12). Conclusion: The Omicron variant causes higher symptom burden in children compared with wild-type/Alpha and lower in adults, possibly due to previous vaccination. A shift in symptoms occurred with reduction in loss of smell/taste for Omicron. No additional effect of booster vaccination on Omicron symptom burden was observed.

AB - Objectives: We compared age-stratified SARS-CoV-2 symptomatology of wild-type/Alpha vs Omicron BA.1/BA.2 variant infected individuals and the impact of COVID-19 booster vaccination on Omicron symptom burden. Methods: Data from three European prospective household cohorts were used (April 2020 to April 2021 and January to March 2022). Standardized outbreak protocols included (repeated) polymerase chain reaction testing, paired serology, and daily symptom scoring for all household members. Comparative analyses were performed on 346 secondary household cases from both periods. Results: Children <12 years (all unvaccinated) experienced more symptoms and higher severity scores during Omicron compared with wild-type/Alpha period (P ≤0.01). In adults, Omicron disease duration and severity were reduced (P ≤ 0.095). Omicron was associated with lower odds for loss of smell or taste (adjusted odds ratio [aOR]: 0.14; 95% CI 0.03-0.50) and higher but non-significant odds for upper respiratory symptoms, fever, and fatigue (aORs: 1.85-2.23). No differences were observed in disease severity or duration between primary vs booster series vaccinated adults (P ≥0.12). Conclusion: The Omicron variant causes higher symptom burden in children compared with wild-type/Alpha and lower in adults, possibly due to previous vaccination. A shift in symptoms occurred with reduction in loss of smell/taste for Omicron. No additional effect of booster vaccination on Omicron symptom burden was observed.

KW - COVID-19 vaccination

KW - Epidemiology

KW - European prospective household studies

KW - Omicron BA.1 and BA.2 variant

KW - SARS-CoV-2 symptom burden

KW - Wild-type/Alpha variant

UR - http://www.scopus.com/inward/record.url?scp=85146461776&partnerID=8YFLogxK

U2 - 10.1016/j.ijid.2022.12.018

DO - 10.1016/j.ijid.2022.12.018

M3 - Article

C2 - 36566773

VL - 128

SP - 140

EP - 147

JO - International journal of infectious diseases : IJID

JF - International journal of infectious diseases : IJID

SN - 1201-9712

ER -

ID: 31711833